Alprazolam-related deaths in Scotland, 2004-2020.

Alprazolam-related deaths in Scotland, 2004-2020.
复制标题

DOI:
10.1177/02698811221104065
复制
发表时间:
2022-09
影响因子:
4.1
通讯作者:
Schifano, Fabrizio
Schifano, Fabrizio
中科院分区:
医学3区
文献类型:
--
作者:
Corkery, John Martin;Guirguis, Amira;Chiappini, Stefania;Martinotti, Giovanni;Schifano, Fabrizio

文献摘要

参考文献

被引文献

相似文献

The benzodiazepine drug alprazolam, a fast-acting tranquiliser, cannot be prescribed on the National Health Service in the United Kingdom. Illicit alprazolam supply and consumption have increased. Concern about increasing numbers of alprazolam-related fatalities started circulating in 2018. However, statistics on this issue are very limited. This study examined patterns in such mortality in Scotland. Statistics on deaths where alprazolam was mentioned in the ‘cause of death’ were obtained from official mortality registers. Anonymised Scottish case-level data were obtained. Data were examined in respect of the characteristics of decedents and deaths using descriptive statistics. Scotland registered 370 deaths in 2004–2020; 366 of these occurred in 2015–2020: most involved males (77.1%); mean age 39.0 (SD 12.6) years. The principal underlying cause of death was accidental poisoning: opiates/opioids (77.9%); sedatives/hypnotics (15.0%). Two deaths involved alprazolam alone. Main drug groups implicated: opiates/opioids (94.8%), ‘other benzodiazepines’ (67.2%), gabapentinoids (42.9%), stimulants (30.1%), antidepressants (15.0%). Two-thirds (64.2%) involved combinations of central nervous system (CNS) depressants. Alprazolam-related deaths are likely due to an increasing illicit supply. The fall in deaths in 2019–2020 is partially due to increased use of designer benzodiazepines. Treatment for alprazolam dependence is growing. Clinicians need to be aware of continuing recreational alprazolam use. When such consumption occurs with CNS depressants, overdose and death risks increase. More awareness of alprazolam contributing to deaths, especially in conjunction with other CNS depressants, is needed by consumers and clinicians. Improved monitoring of illicit supplies could identify emerging issues of medicines’ abuse.
DOI: 10.2174/1389200218666171108163817
发表时间: 2018-01-01
影响因子: 2.3
作者:
Corkery, John M.;Loi, Barbara;Schifano, Fabrizio
通讯作者: Schifano, Fabrizio
DOI: 10.1177/009127009703700111
发表时间: 1997-01-01
影响因子: 2.9
作者:
Ciraulo, DA;Barnhill, JG;Shader, RI
通讯作者: Shader, RI
DOI: 10.1093/jat/bkab073
发表时间: 2021-06-19
影响因子: 2.5
作者:
Bishop-Freeman, Sandra C.;Friederich, Laura W.;Hudson, Jason S.
通讯作者: Hudson, Jason S.
DOI: 10.1016/s2468-2667(20)30288-7
发表时间: 2021-03
期刊: The Lancet. Public health
影响因子: --
作者:
Carr MJ;Steeg S;Webb RT;Kapur N;Chew-Graham CA;Abel KM;Hope H;Pierce M;Ashcroft DM
通讯作者: Ashcroft DM
DOI: 10.1002/dta.3119
发表时间: 2021-07-01
影响因子: 2.9
作者:
Blakey, Karen;Thompson, Amanda;Griffiths, Andrew
通讯作者: Griffiths, Andrew